Verastem Inc., of Boston, said it dosed the first patient in a phase I/II trial testing avelumab (Merck KGaA and Pfizer Inc.), a fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s defactinib, an FAK inhibitor, in patients with advanced ovarian cancer.